

REMARKS***Pending claims***


Claims 1, 3, 5, 6, 21-23, and 26 have been amended to more clearly point out and distinctly claim the invention. These amendments do not contain new matter and are fully supported by the specification. After these amendments are entered, twenty four (24) Claims (claims 1, 3-10, and 12-26) are pending.

Claims Rejections under 35 U.S.C §112

Claims 1, 3-9 and 20-23 were rejected under 35 U.S.C. §112, the second paragraph. Applicants submit that this claim rejection over claims 1, 3-9 and 20-23 has been overcome by the amendments of claims. Applicants respectfully request withdrawal of the 35 U.S.C. §112, the second paragraph rejection.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. Please address all correspondence to Thomas Hoxie, Novartis Corporation, Corporate Intellectual Property, One Health Plaza, Bldg. 430, East Hanover, NJ 07936-1080. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,



Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date: Dec. 12, 2003

Novartis Corporation
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080